NCT02477618Phase 3Completed

A Study With SAGE-547 for Super-Refractory Status Epilepticus

Study sponsor: Supernus Pharmaceuticals, Inc. · SUPN

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2017-07-18Actual
Enrollment · participants132Actual
Source updated2025-10-14Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.